Aminolevulinic Acid
- Generic Name
- Aminolevulinic Acid
- Brand Names
- Ameluz, Gliolan, Levulan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9NO3
- CAS Number
- 106-60-5
- Unique Ingredient Identifier
- 88755TAZ87
- Background
A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
- Indication
用于皮肤癌及鲍温病、牛皮癣，男性尿道尖锐湿疣等皮肤病。可治疗消化道肿瘤、口腔癌。可诊断和治疗膀胱癌、尿路上皮肿瘤。能阻止血管成形术后在狭窄。
- Associated Conditions
- Actinic Cheilitis, Actinic Keratoses of the face, Actinic Keratoses of the scalp, Actinic Keratosis (AK) of the Upper Extremity, Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma in Situ (CSCCis), Glioma
- Associated Therapies
- -
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Donald Basel
- Target Recruit Count
- 30
- Registration Number
- NCT02728388
- Locations
- 🇺🇸
Donald G Basel, Milwaukee, Wisconsin, United States
The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 32
- Registration Number
- NCT02594644
- Locations
- 🇺🇸
University of California-Davis, Department of Dermatology, Sacramento, California, United States
Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)
- Conditions
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2019-08-28
- Target Recruit Count
- 72
- Registration Number
- NCT02464709
- Locations
- 🇫🇮
Vaasa Central Hospital, Vaasa, Finland
🇫🇮Tampere University Hospital, Tampere, Finland
🇫🇮Päijät-Häme Central Hospital, Lahti, Finland
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
- Conditions
- Interventions
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- DUSA Pharmaceuticals, Inc.
- Target Recruit Count
- 166
- Registration Number
- NCT02239679
- Locations
- 🇺🇸
UCSD Dermatology, San Diego, California, United States
🇺🇸Sadick Research Group, New York, New York, United States
🇺🇸Shideler Clinical Research Center, Carmel, Indiana, United States
ALA-induced PpIX Fluorescence During Brain Tumor Resection
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- David W. Roberts
- Target Recruit Count
- 540
- Registration Number
- NCT02191488
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome
- Conditions
- Interventions
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Edward Maytin, MD, PhD
- Target Recruit Count
- 3
- Registration Number
- NCT02157623
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
5-ALA in Recurrent Glioma
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2017-01-06
- Target Recruit Count
- 60
- Registration Number
- NCT02119338
- Locations
- 🇺🇸
Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
The Use of Microneedles in Photodynamic Therapy
- Conditions
- Interventions
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2017-06-15
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 51
- Registration Number
- NCT01812837
- Locations
- 🇺🇸
UC Davis, Dermatology, Sacramento, California, United States
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2012-04-11
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Michael Vogelbaum, MD, PhD
- Target Recruit Count
- 8
- Registration Number
- NCT01575275
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
- First Posted Date
- 2011-12-30
- Last Posted Date
- 2017-01-05
- Target Recruit Count
- 6
- Registration Number
- NCT01502605
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.